Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AYTU BIOPHARMA, INCAYTU · Entity 7560 | Chief Financial Officer | March 16, 2017 | March 17, 2017 |
| Aclarion, Inc.ACON · Entity 8157 | CFO | August 14, 2026 | August 18, 2026 |
| Charlotte's Web Holdings, Inc.CWBHF · Entity 2770 | Chief Financial Officer | June 17, 2022 | June 21, 2022 |
| CytoDyn Inc.CYDY · Entity 5856 | Director | June 18, 2019 | June 20, 2019 |
| NewAge, Inc.NBEV · Entity 129046 | Chief Financial Officer | July 02, 2021 | July 07, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AYTU BIOPHARMA, INC
Report date March 16, 2017 · Filed March 17, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $3.23 · Expires 2015-11-11 | Direct | 0 |
Reported balance
After 2017-03-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-03-16 · Disposition to issuer · Disposed 20,834 · Balance 0 F4: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F2: These options are 100% vested. |
| Employee Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $3.23 · Expires 2026-07-07 | Direct | 0 |
Reported balance
After 2017-03-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-03-16 · Disposition to issuer · Disposed 25,000 · Balance 0 F4: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F3: 33.3% vests on the one year, two year and three year anniversary of the date of grant, subject to the Grantee's service as an employee on such dates. |
| Employee Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2015-11-11 | Direct | 20,834 |
Reported balance
After 2017-03-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-03-16 · Grant · Acquired 20,834 · Balance 20,834 F4: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F2: These options are 100% vested. |
| Employee Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2026-07-07 | Direct | 25,000 |
Reported balance
After 2017-03-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-03-16 · Grant · Acquired 25,000 · Balance 25,000 F4: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F3: 33.3% vests on the one year, two year and three year anniversary of the date of grant, subject to the Grantee's service as an employee on such dates. |
| Common StockSEC Table I · non-derivative | Direct | 340,231 |
Reported balance
Holding disclosure · report date 2017-03-16 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 340,231 F1: Of these shares, 165,000 shares are restricted shares that vest on July 7, 2026, subject to earlier vesting in certain situations. |
| Warrant to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.86 · Expires 2021-11-02 | Direct | 0 |
Reported balance
Holding disclosure · report date 2017-03-16 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: Of these shares, 165,000 shares are restricted shares that vest on July 7, 2026, subject to earlier vesting in certain situations.
F2: These options are 100% vested.
F3: 33.3% vests on the one year, two year and three year anniversary of the date of grant, subject to the Grantee's service as an employee on such dates.
F4: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option.
Aclarion, Inc.
Report date August 14, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,000 |
Reported balance
After 2026-08-14 transaction · row 1
1 source rowRow 1 · 2026-08-14 · Purchase · Acquired 10,000 · Balance 60,000 F1: The Reporting Person purchased common stock on the public market on 08-14-2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person purchased common stock on the public market on 08-14-2026.
Charlotte's Web Holdings, Inc.
Report date June 17, 2022 · Filed June 21, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.44 · Expires 2032-06-17 | Direct | 1,200,000 |
Reported balance
After 2022-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-17 · Grant · Acquired 1,200,000 · Balance 1,200,000 F1: The option agreement provides that the option becomes exercisable in 2 equal annual installments beginning on 6/18/2023. The option was granted on 6/17/2022 in connection with Mr. Gould's appointment as an officer of the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The option agreement provides that the option becomes exercisable in 2 equal annual installments beginning on 6/18/2023. The option was granted on 6/17/2022 in connection with Mr. Gould's appointment as an officer of the Company.
CytoDyn Inc.
Report date June 18, 2019 · Filed June 20, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.52 · Expires 2029-06-18 | Direct | 100,000 |
Reported balance
After 2019-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-18 · Grant · Acquired 100,000 · Balance 100,000 F1: The options will vest in four equal quarterly installments, commencing on September 1, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The options will vest in four equal quarterly installments, commencing on September 1, 2019.
NewAge, Inc.
Report date July 02, 2021 · Filed July 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 331,255 |
Reported balance
After 2021-07-02 transaction · row 1
1 source rowRow 1 · 2021-07-02 · Tax withholding · Disposed 73,110 · Balance 331,255 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 02, 2016 Filed Nov 4, 2016 20:58 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | PurchaseCommon Stock | 66,666 | $1.50 | $99,999.00 |
DisclosureSEC source: 0001638599-16-001508 · doc4_4277.xml · nonDerivative · entry 1 Gould Gregory A · CIK 0001252905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,565 F1 · price: The shares of stock and warrants were purchased at a purchase price per unit of $1.50. F2 · balance_after: Of these shares, 165,000 shares are restricted shares that vest on July 7, 2026, subject to earlier vesting in certain situations. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.